ISSN: 0361-8609
Journal Home
Journal Guideline
American Journal of Hematology Q1 Unclaimed
American Journal of Hematology is a journal indexed in SJR in Hematology with an H index of 130. It has a price of 3500 €. It has an SJR impact factor of 2,607 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 2,607.
American Journal of Hematology focuses its scope in these topics and keywords: cell, leukemia, iron, disease, survival, hematopoietic, lymphoma, syndrome, immunoglobulin, myelodysplastic, ...
Type: Journal
Type of Copyright:
Languages: English
Open Access Policy: Open Choice
Type of publications:
Publication frecuency: -
3500 €
Inmediate OANPD
Embargoed OA0 €
Non OAMetrics
2,607
SJR Impact factor130
H Index361
Total Docs (Last Year)1029
Total Docs (3 years)11402
Total Refs5274
Total Cites (3 years)522
Citable Docs (3 years)4.83
Cites/Doc (2 years)31.58
Ref/DocOther journals with similar parameters
Journal of Hematology and Oncology Q1
Blood Q1
Blood Cancer Journal Q1
The Lancet Haematology Q1
Leukemia Q1
Compare this journals
Aims and Scope
Best articles by citations
Polymorphisms of drug-metabolizing enzymes and risk of childhood acute lymphoblastic leukemia
View moreLong-standing Bell's palsy and ipsilateral conjunctival maltoma
View moreAcute pancreatitis during sickle cell vaso-occlusive painful crisis
View moreBulky plasmacytoma of the skull with intracranial involvement
View moreA non-immunological phospholipid-dependent coagulation inhibitor associated with IgG?-type multiple myeloma
View morePhiladelphia chromosome-positive acute lymphoblastic leukemia after therapy for langerhans cell histiocytosis
View moreEnhanced low shear stress induced platelet aggregation by Shiga-like toxin 1 purified fromEscherichia coli O157
View moreBone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study
View moreClinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia
View moreVenous thromboembolism prevention in the acutely ill medical patient: A review of the literature and focus on special patient populations
View moreClumping of plasma cells: A pitfall in the diagnosis of plasma cell leukemia
View moreSuccessful hematopoietic stem-cell transplantation in multicentric Castleman disease complicated by POEMS syndrome
View moreSuccessful treatment of persistent erythroid aplasia caused by parvovirus B19 infection in a patient with common variable immunodeficiency with low-dose immunoglobulin
View moreImmune thrombocytopenia attributed to brucellosis and other mechanisms ofBrucella-induced thrombocytopenia
View moreDeferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial
View moreResidual leukemic blasts or regenerating normal precursors? The hematologist's dilemma
View morePersistent parvovirus B19 related anemia of seven years' duration in an HIV-infected patient: Complete remission associated with highly active antiretroviral therapy
View moreTreatment of agnogenic myeloid metaplasia with danazol: A report of four cases
View moreCase of Schwachman's syndrome with intermittent neutropenia and lymphocyte subset disturbances
View moreTargeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation
View morePancytopenia due to extensive hemophagocytosis following anti-tubercular treatment
View moreUreteric obstruction by retroperitoneal lymphoplasmacytic lymphoma
View moreMini-BEAM and autologous hematopoietic stem-cell transplant for treatment of post-transplant lymphoproliferative disorders
View moreFirst observation of homozygous hemoglobin hamadan (B 56 (D7) GLY-ARG) and beta thalassemia (-29 G>A)- hemoglobin Hamadan combination in a Turkish family
View more
Comments